Cargando…

Prevalence of multimorbidity in men of African descent with and without prostate cancer in Soweto, South Africa

OBJECTIVE: With increases in chronic disease, men with prostate cancer are likely to have at least one other chronic health condition. The burden and complexity of each additional chronic disease may complicate prostate cancer treatment and reduce survival. In this paper, we describe the frequency o...

Descripción completa

Detalles Bibliográficos
Autores principales: Mapanga, Witness, Norris, Shane A., Craig, Ashleigh, Pumpalova, Yoanna, Ayeni, Oluwatosin A., Chen, Wenlong Carl, Jacobson, Judith S., Neugut, Alfred I., Muchengeti, Mazvita, Pentz, Audrey, Doherty, Sean, Minkowitz, Shauli, Haffejee, Mohammed, Rebbeck, Tim, Joffe, Maureen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578630/
https://www.ncbi.nlm.nih.gov/pubmed/36256648
http://dx.doi.org/10.1371/journal.pone.0276050
_version_ 1784812004982128640
author Mapanga, Witness
Norris, Shane A.
Craig, Ashleigh
Pumpalova, Yoanna
Ayeni, Oluwatosin A.
Chen, Wenlong Carl
Jacobson, Judith S.
Neugut, Alfred I.
Muchengeti, Mazvita
Pentz, Audrey
Doherty, Sean
Minkowitz, Shauli
Haffejee, Mohammed
Rebbeck, Tim
Joffe, Maureen
author_facet Mapanga, Witness
Norris, Shane A.
Craig, Ashleigh
Pumpalova, Yoanna
Ayeni, Oluwatosin A.
Chen, Wenlong Carl
Jacobson, Judith S.
Neugut, Alfred I.
Muchengeti, Mazvita
Pentz, Audrey
Doherty, Sean
Minkowitz, Shauli
Haffejee, Mohammed
Rebbeck, Tim
Joffe, Maureen
author_sort Mapanga, Witness
collection PubMed
description OBJECTIVE: With increases in chronic disease, men with prostate cancer are likely to have at least one other chronic health condition. The burden and complexity of each additional chronic disease may complicate prostate cancer treatment and reduce survival. In this paper, we describe the frequency of multimorbid chronic diseases, HIV and depression among men in Soweto, South Africa (SA) with and without prostate cancer and determine whether the presence of multimorbid diseases is associated with metastatic and high-risk, non-metastatic prostate cancer. METHODS: A population-based case-control study on prostate cancer was conducted among black men in Soweto. All participants completed a baseline survey on sociodemographics, lifestyle, and comorbid medical conditions. All participants completed a depression screening survey and HIV testing at enrolment. Blood pressure measurements and blood testing for fasting glucose, total cholesterol, and high-density lipoprotein were performed on a subset of randomly selected cases and controls. For men with prostate cancer, clinical T staging was assessed with the digital rectal examination, the diagnosis was confirmed with a biopsy and PSA levels were assessed at presentation. The metastatic staging was assessed by bone scans, and this was confirmed with PSMA PET scans, CT scans and X-rays, standard for our resource-constrained setting. Normal PSA scores were used as an inclusion criterion for controls. RESULTS: Of the 2136 men (1095 with prostate cancer and 1041 controls) included in the analysis, 43.0% reported at least one chronic metabolic disease; 24.1% reported two metabolic diseases; 5.3% reported three metabolic diseases; and 0.3% reported four metabolic diseases. Men with prostate cancer were more likely to report a multimorbid chronic metabolic disease compared to controls (p<0.001) and more likely to test positive for HIV (p = 0.05). The majority of men (66.2%) reported at least one metabolic disease, tested negative for HIV and had a negative depression screen. The clinical characteristics of men with prostate cancer, were as follows: 396 (36.2%) had a Gleason score of 8 and above; 552 (51.3%) had a PSA score of >20ng/ml; 233 (21.7%) had confirmed metastatic prostate cancer at diagnosis. Older age was associated with metastatic prostate cancer (OR = 1.043 95% CI:1.02–1.07) and NCCN defined high-risk non-metastatic prostate cancer (OR = 1.03 95% CI:1.01–1.05), whilst being hypertensive was protective (OR = 0.63 95% CI:0.47–0.84 and OR = 0.55 95% CI:0.37–0.83) respectively for metastatic and high-risk, non-metastatic prostate cancer. CONCLUSION: The high prevalence of multimorbid metabolic diseases and HIV among men with prostate cancer represents a public health concern in South Africa. There is a need to effectively address multiple chronic diseases among men with prostate cancer by incorporating coordinated care models.
format Online
Article
Text
id pubmed-9578630
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-95786302022-10-19 Prevalence of multimorbidity in men of African descent with and without prostate cancer in Soweto, South Africa Mapanga, Witness Norris, Shane A. Craig, Ashleigh Pumpalova, Yoanna Ayeni, Oluwatosin A. Chen, Wenlong Carl Jacobson, Judith S. Neugut, Alfred I. Muchengeti, Mazvita Pentz, Audrey Doherty, Sean Minkowitz, Shauli Haffejee, Mohammed Rebbeck, Tim Joffe, Maureen PLoS One Research Article OBJECTIVE: With increases in chronic disease, men with prostate cancer are likely to have at least one other chronic health condition. The burden and complexity of each additional chronic disease may complicate prostate cancer treatment and reduce survival. In this paper, we describe the frequency of multimorbid chronic diseases, HIV and depression among men in Soweto, South Africa (SA) with and without prostate cancer and determine whether the presence of multimorbid diseases is associated with metastatic and high-risk, non-metastatic prostate cancer. METHODS: A population-based case-control study on prostate cancer was conducted among black men in Soweto. All participants completed a baseline survey on sociodemographics, lifestyle, and comorbid medical conditions. All participants completed a depression screening survey and HIV testing at enrolment. Blood pressure measurements and blood testing for fasting glucose, total cholesterol, and high-density lipoprotein were performed on a subset of randomly selected cases and controls. For men with prostate cancer, clinical T staging was assessed with the digital rectal examination, the diagnosis was confirmed with a biopsy and PSA levels were assessed at presentation. The metastatic staging was assessed by bone scans, and this was confirmed with PSMA PET scans, CT scans and X-rays, standard for our resource-constrained setting. Normal PSA scores were used as an inclusion criterion for controls. RESULTS: Of the 2136 men (1095 with prostate cancer and 1041 controls) included in the analysis, 43.0% reported at least one chronic metabolic disease; 24.1% reported two metabolic diseases; 5.3% reported three metabolic diseases; and 0.3% reported four metabolic diseases. Men with prostate cancer were more likely to report a multimorbid chronic metabolic disease compared to controls (p<0.001) and more likely to test positive for HIV (p = 0.05). The majority of men (66.2%) reported at least one metabolic disease, tested negative for HIV and had a negative depression screen. The clinical characteristics of men with prostate cancer, were as follows: 396 (36.2%) had a Gleason score of 8 and above; 552 (51.3%) had a PSA score of >20ng/ml; 233 (21.7%) had confirmed metastatic prostate cancer at diagnosis. Older age was associated with metastatic prostate cancer (OR = 1.043 95% CI:1.02–1.07) and NCCN defined high-risk non-metastatic prostate cancer (OR = 1.03 95% CI:1.01–1.05), whilst being hypertensive was protective (OR = 0.63 95% CI:0.47–0.84 and OR = 0.55 95% CI:0.37–0.83) respectively for metastatic and high-risk, non-metastatic prostate cancer. CONCLUSION: The high prevalence of multimorbid metabolic diseases and HIV among men with prostate cancer represents a public health concern in South Africa. There is a need to effectively address multiple chronic diseases among men with prostate cancer by incorporating coordinated care models. Public Library of Science 2022-10-18 /pmc/articles/PMC9578630/ /pubmed/36256648 http://dx.doi.org/10.1371/journal.pone.0276050 Text en © 2022 Mapanga et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Mapanga, Witness
Norris, Shane A.
Craig, Ashleigh
Pumpalova, Yoanna
Ayeni, Oluwatosin A.
Chen, Wenlong Carl
Jacobson, Judith S.
Neugut, Alfred I.
Muchengeti, Mazvita
Pentz, Audrey
Doherty, Sean
Minkowitz, Shauli
Haffejee, Mohammed
Rebbeck, Tim
Joffe, Maureen
Prevalence of multimorbidity in men of African descent with and without prostate cancer in Soweto, South Africa
title Prevalence of multimorbidity in men of African descent with and without prostate cancer in Soweto, South Africa
title_full Prevalence of multimorbidity in men of African descent with and without prostate cancer in Soweto, South Africa
title_fullStr Prevalence of multimorbidity in men of African descent with and without prostate cancer in Soweto, South Africa
title_full_unstemmed Prevalence of multimorbidity in men of African descent with and without prostate cancer in Soweto, South Africa
title_short Prevalence of multimorbidity in men of African descent with and without prostate cancer in Soweto, South Africa
title_sort prevalence of multimorbidity in men of african descent with and without prostate cancer in soweto, south africa
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578630/
https://www.ncbi.nlm.nih.gov/pubmed/36256648
http://dx.doi.org/10.1371/journal.pone.0276050
work_keys_str_mv AT mapangawitness prevalenceofmultimorbidityinmenofafricandescentwithandwithoutprostatecancerinsowetosouthafrica
AT norrisshanea prevalenceofmultimorbidityinmenofafricandescentwithandwithoutprostatecancerinsowetosouthafrica
AT craigashleigh prevalenceofmultimorbidityinmenofafricandescentwithandwithoutprostatecancerinsowetosouthafrica
AT pumpalovayoanna prevalenceofmultimorbidityinmenofafricandescentwithandwithoutprostatecancerinsowetosouthafrica
AT ayenioluwatosina prevalenceofmultimorbidityinmenofafricandescentwithandwithoutprostatecancerinsowetosouthafrica
AT chenwenlongcarl prevalenceofmultimorbidityinmenofafricandescentwithandwithoutprostatecancerinsowetosouthafrica
AT jacobsonjudiths prevalenceofmultimorbidityinmenofafricandescentwithandwithoutprostatecancerinsowetosouthafrica
AT neugutalfredi prevalenceofmultimorbidityinmenofafricandescentwithandwithoutprostatecancerinsowetosouthafrica
AT muchengetimazvita prevalenceofmultimorbidityinmenofafricandescentwithandwithoutprostatecancerinsowetosouthafrica
AT pentzaudrey prevalenceofmultimorbidityinmenofafricandescentwithandwithoutprostatecancerinsowetosouthafrica
AT dohertysean prevalenceofmultimorbidityinmenofafricandescentwithandwithoutprostatecancerinsowetosouthafrica
AT minkowitzshauli prevalenceofmultimorbidityinmenofafricandescentwithandwithoutprostatecancerinsowetosouthafrica
AT haffejeemohammed prevalenceofmultimorbidityinmenofafricandescentwithandwithoutprostatecancerinsowetosouthafrica
AT rebbecktim prevalenceofmultimorbidityinmenofafricandescentwithandwithoutprostatecancerinsowetosouthafrica
AT joffemaureen prevalenceofmultimorbidityinmenofafricandescentwithandwithoutprostatecancerinsowetosouthafrica